FDA Authorizes Simparica TRIO for Screwworm in Dogs
Silver Spring, Maryland, August 13, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Silver Spring, Maryland, August 13, 2026 The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization...
PARSIPPANY, N.J., August 13, 2026 Zoetis Inc. announced that the U.S. Food and Drug Administration has issued an Emergency...
PARSIPPANY, N.J., December 5, 2025 — Zoetis Inc. announced that Health Canada has approved Portela™ (relfovetmab injection) for the...
PARSIPPANY, N.J. — December 11, 2025 — Zoetis Inc., the world’s leading animal health company, announced that its Board...
SAN FRANCISCO, December 3, 2025 — Junevity today announced the expansion of its seed funding round to $20 million...
PARSIPPANY, N.J., December 3, 2025 — Zoetis has highlighted its R&D leadership, expanding innovation strategy, and long-term growth outlook...
Parsippany, New Jersey / Brussels, October 29, 2025 — Zoetis Inc. today announced that the European Commission has granted...
Parsippany, NJ – September 30, 2025 – Zoetis Inc. announced that Dectomax®-CA1 Injectable has received conditional approval from the...
